Sen. Warren pitches a Big Pharma 'swear jar'; U.K. biotech VC jumped 41% in 2014;

@FierceBiotech: EuroBiotech: EU IPOs obliterate recent highs, U.K. VC funding tops $700M, Woodford backs microbiome play. Report | Follow @FierceBiotech

@JohnCFierce: Interviewed the CEO at the new CAR-T player. Their CSO also worked on Bellicum program. Story | Follow @JohnCFierce

@DamianFierce: $MDCO's Clive Meanwell has by far the best name among biopharma CEOs. At least until someone appoints Guy Smiley. | Follow @DamianFierce

> Sen. Elizabeth Warren (D-MA) has a novel plan for punishing Big Pharma malfeasance: Drugmakers that settle federal criminal charges would have to bequeath 1% of their annual profits to the National Institutes of Health for 5 years thereafter. "It's like a swear jar," Warren said. More

> Former Chimerix ($CMRX) CEO Kenneth Moch, once at the center of a compassionate use controversy over the company's antiviral treatment, unexpectedly stepped down last year. Bloomberg Businessweek takes a detailed look at just what happened. Item

> U.K. life sciences firms banked about $713 million in venture capital last year, according to CB Insights, a 41% jump over 2013. News

Medical Device News

@FierceMedDev: Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Welch Allyn buys eye exam provider, signaling move into services. Article | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Weber; Bonjour, Bohuon? FiercePharma article | Follow @EmilyWFierce

> Profit down 12% at Intuitive Surgical, but procedure volume up due to strength abroad and in general surgery. More

> France's bioMérieux and Astute Medical join forces on acute kidney injury test. Article

Pharma News

@FiercePharma: ICYMI yesterday: Pfizer wins recommendation for Prevenar expansion in Europe. Story | Follow @FiercePharma

@EricPFierce: UAE-based Gulf Pharmaceuticals intends to build a $50M insulin plant in Ethiopia. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ex-Sanofi chief Viehbacher makes a $5M-plus severance deal. Article | Follow @CarlyHFierce

> Challenger says 2015 a year to send out your resume, pharma folk. Story

> GSK refutes reports the ax is about to fall on jobs in China. News

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.